In this 26-week , randomized , open-label , multinational , treat-to-target trial , participants ( mean age 58.7 years , duration of diabetes 13 years , BMI 29.3 kg/m ( 2 ) , and HbA1c 8.4 % [ 68 mmol/mol ] ) were exposed ( 1:1 ) to BID injections of IDegAsp ( n = 224 ) or BIAsp 30 ( n = 222 ) , administered with breakfast and the main evening meal and dose titrated to a self-measured premeal plasma glucose ( PG ) target of 4.0-5 .0 mmol/L .